The Bob Harrington Show

 
 

The Bob Harrington Show

  • Yes, There Is a Role for Poetry and Fiction in a Pandemic   'They fancy themselves free. And no one will ever be free so long as there are pestilences,' wrote Camus in 'The Plague', which Abraham Verghese sees as relevant to our collective experience of COVID-19.
  • A Cardiologist's Search for Medicine's Lost Heart   Cardiologist Lisa Rosenbaum seeks meaning in her work as a physician and correspondent for the New England Journal of Medicine, a quest first started by her grandfather who was also a physician-writer.
  • Cardiology's Hottest Trial of 2019 and Healthcare 2020   Bob Harrington and Mike Gibson continue their review of 2019 with the 'hottest trial of the year' and what to expect in healthcare in 2020.
  • Cardiology 2019: Top Trials in Review   'It's like we're in the '90s again.' Drs Gibson and Harrington review top cardiology trials on revascularization, lipid management, and antithrombotics in part 1 of their annual wrap-up.
  • How a Snakebite and Sudden Death Led to Cardiology and Writing   A family history of sudden death was the impetus for author Sandeep Jauhar's fascination with the heart, which led to a career in cardiology and his latest book Heart: A History.
  • 'I Was That Kid': Dr Quinn Capers Inspires #BlackMenInMedicine   Fewer black men are going into medicine today than in 1978. Drs Harrington and Capers discuss how to increase diversity in medicine and why it's important for caregivers to reflect the population they treat.
  • Calling Time on the Failure in Heart Failure   Optimal medical therapy and recent advances show that heart failure is preventable and not obligatory, Clyde Yancy tells Bob Harrington.
  • Cardiology Topics to Watch for in 2019 Wearables, aspirin for secondary prevention, AI and machine learning, and drug pricing are among the topics to keep an eye on in 2019, according to cardiologists Drs Harrington and Gibson.
  • 'Hope' and 'Optimism' for Reducing Physician Burnout   It's not all dire. Tait Shanafelt, MD, is witnessing improvement and momentum in the field of clinician wellness. Learn about his journey from hematology to chief wellness officer.
  • The Top Cardiology Trials of 2018 in Review Contrasting studies on the benefits of percutaneous mitral valve repair and a fall from grace for aspirin make the list for Bob Harrington and Mike Gibson. Find out what else piqued their interest.
  • For Better Clinical Research, Collaborate With Statisticians   Volunteering at a VA hospital was the first step in biostatistician Frank Harrell's illustrious career in cardiovascular research.
  • Data Torture and Dumb Analyses: Missteps With Big Data   Despite the vastness of available data, don't forget the basics, warns biostatistician Frank Harrell in this conversation with Bob Harrington.
  • Cardio Twitter: An Essential Tool for Staying Current   Drs Harrington and Yeh discuss the pros, cons, and cautions of using Twitter in the cardiovascular community.
  • Incentivizing Cardiologists to Do the Right Thing   Drs Harrington and Joynt Maddox discuss the move from volume-based to performance-based payment models and how to develop evidence-based quality metrics that make clinical sense.
  • Hot Topics in Cardiology: Tech, Twitter, and the Hypertension Guidelines   Drs Harrington and Gibson discuss burning issues in medicine, including artificial intelligence, social media, wearable tech, and the new hypertension guidelines.
  • 7 Cardiology Trials to Look for in 2018   Trials on PCSK9 inhibitors, antiplatelets, anticoagulants, and even catheter ablation of atrial fibrillation are among Drs Harrington and Gibson's picks for what to look for in 2018.
  • Public Reporting as Public Shaming, and Potential Solutions   A recent viewpoint by Dr Bhatt against public reporting of PCI outcomes garnered a lot of support in the cardiology community and beyond. Dr Harrington asks how it can be done better.
  • The Top Cardiology Trials of 2017 in Review   In this annual tradition, Drs Harrington and Gibson discuss their picks for the top cardiology trials of the year, covering PCSK9 inhibitors, anti-inflammatory and anthithrombotic drugs, and PCI.
  • The Complexities Behind High Prescription Prices   Drs Harrington and Kesselheim discuss the varied reasons why prescription drugs are so pricey and whether policies can interrupt this alarming trend.
  • Life After the FDA: Mining Data and Reducing Disparities   Dr Califf talks about his new role at Verily and how data mining and data sharing could reduce disparities in care and improve patient outcomes.